Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H2N2 1960 AA ca recombinant vaccine
- Development stage
- Phase 1
- Lead developer
- University of Michigan
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
The **H2N2 1960 AA ca recombinant vaccine** is a live attenuated, cold-adapted, and temperature-sensitive influenza A (H2N2) virus vaccine derived from the A/Ann Arbor/6/60 strain. It is designed as a candidate for pandemic preparedness against potential re-emergence of human H2N2 influenza viruses. The "recombinant" aspect refers to its derivation using reverse genetics or reassortment techniques to produce an attenuated virus that can replicate efficiently in the cooler upper respiratory tract but not in warmer lower airways. This induces protective immune responses without causing disease[2]. The primary mechanism of action is induction of humoral and cellular immunity against hemagglutinin (HA) and neuraminidase (NA) antigens specific to the H2 subtype[3]. The main indication is prevention of infection by influenza A/Human/Hong Kong/H3 or similar strains; it has been evaluated in phase I clinical trials for safety and immunogenicity[2].
- Other names
- live attenuated H2N2 influenza virus vaccinecold-adapted H2N2 1960 AA catemperature-sensitive H2N2 1960 AA ca
02
Targets
N2 (Influenza A neuraminidase N2)HA-2 (Minor histocompatibility antigen HA-2)
Beyond the preview
Go deeper on H2N2 1960 AA ca recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H2N2 1960 AA ca recombinant vaccine.